Biosimilar medicine authorized by the AEMPS
ACTIVE PRINCIPLE: trastuzumab
INDICATION: Breast cancer Stomach cancer
DATE: 28/02/2019
STATUS: Authorized
MORE INFORMATION
Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.
SUBSCRIBE
